BioNTech is betting big on British science, committing up to £1bn over the next decade to expand its regional R&D footprint. Backed by a £129m government grant—one of the largest ever awarded to a pharma firm in the UK—the move signals a major boost for oncology trials, AI-led drug development, and personalised mRNA therapies.

New R&D centres in Cambridge and a London HQ with an AI hub are central to the plan, which aims to create 400+ highly skilled roles. Beyond infrastructure, the partnership accelerates BioNTech’s mission to bring investigational cancer immunotherapies to 10,000 patients by 2030.

For decision makers, this is a signal: the UK's life sciences sector isn’t just growing—it’s being strategically positioned as a global leader in next-gen medicine.

Read the full article for what this means for pharma’s future in the UK.